Resource: FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine
Source: U.S. Food and Drug Administration
Synopsis: The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older.
Comment: The Moderna vaccine has a 94.1% efficacy, needs to be stored at -4°F and there are 20 million doses available by December 31. In contrast, the Pfizer vaccine has a 95% efficacy, needs to be stored at -94°F and there are 50 million doses available by December 31. There are three other vaccines which the FDA is currently working on. These vaccines include the following companies: Johnson and Johnson, AstraZeneca, and Novavax. All three are looking to be authorized by the FDA in expedited fashion in accordance with operation warp speed.
